MAPT and Alzheimer disease: Recent studies have demonstrated that HDAC6 regulates tau phosphorylation and either genetic ablation or pharmacological inhibition of HDAC6 ameliorates cognitive deficits in AD models by reducing Aβ and tau pathology [30, 31].